Mazdutide 10mg

Description

Introduction: The World’s First Approved Dual GCG/GLP-1 Receptor Agonist

Mazdutide represents a groundbreaking advancement in weight loss peptide research, earning distinction as the world’s first dual GCG/GLP-1 receptor agonist to get control approval for chronic weight care. In June 2025, China’s National Medical Products Use (NMPA) approved Mazdutide based on exceptional Phase 3 clinical trial data showing up to 20.1% weight loss—surpassing most single-receptor agonists and rivaling the most advanced weight loss drugs available. This historic approval validates a revolutionary approach to obesity treatment that combines the proven benefits of GLP-1 receptor start with the body benefits of glucagon receptor boost.

The growth of Mazdutide, also known as IBI362 or LY3305677, represents years of collaborative research between Innovent Biologics and Eli Lilly. As a synthetic mammalian oxyntomodulin (OXM) analog, Mazdutide was mainly engineered to start both GLP-1 receptors and glucagon receptors in a balanced manner, creating combined effects that neither receptor alone can achieve. This dual mechanism addresses obesity through multiple paired pathways: GLP-1 start suppresses appetite and enhances insulin secretion, while glucagon start increases energy output and improves hepatic fat body function. The result is superior weight loss effect combined with full body benefits that extend far beyond simple weight reduction.

Clinical evidence supporting Mazdutide’s approval is extensive and compelling. The pivotal GLORY-1 Phase 3 trial showed 14.8% mean weight loss at 48 weeks with the 6mg dose, with 82.8% of participants achieving ≥5% weight loss and 50.6% achieving ≥15% weight loss. The GLORY-2 trial, testing the 9mg dose in moderate-severe obesity, achieved even more impressive results: 20.1% mean weight loss. These outcomes were accompanied by major gains in waist circumference (11cm reduction), liver fat content (65-80% reduction), blood pressure, lipid profiles, and glycemic control. The full nature of these benefits distinguishes Mazdutide from earlier weight loss peptides and positions it as a next-generation treatment option.

PrymaLab’s Mazdutide 10mg peptide represents pharmaceutical-grade quality for serious research uses. Each vial contains 99% pure mazdutide, verified through rigorous third-party testing using high-performance liquid chromatography (HPLC) and mass spectrometry. This exceptional purity ensures consistent, reliable results across experimental protocols. Whether studying dual receptor agonist mechanisms, exploring next-generation weight loss pathways, or studying full body gains, researchers need the highest quality peptides to create meaningful data. Our commitment to quality control and transparency makes PrymaLab the trusted source for Mazdutide research.

The approval of Mazdutide marks a pivotal moment in obesity research and treatment. Named by Fierce Pharma as one of the top ten most expected drugs globally in 2025, Mazdutide represents the convergence of cutting-edge peptide science, robust clinical evidence, and control validation. For researchers, this approval provides confidence in the mechanism’s validity and safety profile, letting more ambitious research protocols. For the field of body disease research, Mazdutide opens new avenues for grasp how dual receptor start can address the complex pathophysiology of obesity more effectively than single-target approaches.

Understanding Mazdutide: From Oxyntomodulin to Dual Agonist Innovation

Mazdutide’s growth story begins with oxyntomodulin (OXM), a naturally occurring peptide hormone secreted by L-cells in the intestine in response to food intake. OXM is a 37-amino acid peptide derived from the same proglucagon precursor that produces GLP-1 and glucagon. Early research revealed that OXM has dual agonist activity, binding to both GLP-1 receptors and glucagon receptors, though with lower affinity than the native hormones. This dual activity sparked interest in OXM’s possible for obesity treatment, as it appeared to combine appetite suppression (via GLP-1) with increased energy output (via glucagon).

However, native OXM had major limitations for treatment use. Its short half-life (minutes) needed continuous infusion for sustained effects. Its relatively weak receptor binding meant high doses were needed to achieve meaningful results. These practical challenges motivated the growth of synthetic OXM analogs with improved pharmacological properties. Mazdutide emerged from this research as an optimized OXM analog mainly engineered to overcome native OXM’s limitations while preserving and enhancing its beneficial dual agonist activity.

Cell-level Engineering and Structure:

Mazdutide’s cell-level structure incorporates several strategic changes to the native OXM sequence:

1. Enhanced Shelf life: Amino acid substitutions and changes protect against enzymatic breakdown by dipeptidyl peptidase-4 (DPP-4) and other peptidases, extending the half-life from minutes to days
2. Balanced Receptor Affinity: The structure is optimized to achieve balanced start of both GLP-1 and glucagon receptors, preventing the hyperglycemia that can occur with too much glucagon start
3. Improved Uptake: Changes enhance under-skin absorption and distribution, letting once-weekly dosing
4. Reduced Immunogenicity: The synthetic structure minimizes possible immune responses that could reduce effect or cause adverse reactions

The result is a peptide that keeps OXM’s dual agonist properties while achieving pharmaceutical-grade shelf life, potency, and safety suitable for chronic weight care.

The Dual Receptor Advantage:

Grasp why dual GCG/GLP-1 start surpasses single-receptor approaches needs examining each pathway’s contributions:

GLP-1 Receptor Start Benefits:

• Appetite suppression through hypothalamic pathways
• Delayed gastric emptying, promoting satiety
• Enhanced glucose-dependent insulin secretion
• Reduced glucagon secretion (in fed state)
• Brain-safe and cardioprotective effects
• Proven safety profile from years of clinical use

Glucagon Receptor Start Benefits:

• Increased energy output and thermogenesis
• Enhanced lipolysis and fat oxidation
• Improved hepatic fat body function
• Reduced hepatic fat synthesis
• Increased hepatic insulin response
• Possible heart benefits

Combined Effects of Dual Start: The magic of Mazdutide lies not just in combining these effects but in their combined interaction. GLP-1 start prevents the hyperglycemia that glucagon alone would cause, while glucagon start enhances the weight loss beyond what GLP-1 alone achieves. The result is superior effect with kept safety—a true advancement over single-receptor agonists.

Clinical Growth Timeline:

Mazdutide’s journey from concept to approval shows rigorous scientific validation:

• 2015-2017: Lab growth and tuning of OXM analog structure
• 2018-2019: Phase 1 trials setting up safety, pharmacokinetics, and dose-ranging
• 2020-2021: Phase 1b trials in obesity and type 2 diabetes populations
• 2022-2023: Phase 2 trials showing effect and best dosing
• 2023-2024: Phase 3 GLORY and DREAMS trials (7 studies total)
• 2024: GLORY-1 and DREAMS trials meet main endpoints, results published in Nature and NEJM
• 2025: China NMPA approval for chronic weight care (June 2025)
• 2025-Present: More Phase 3 trials ongoing (MASH, HFpEF, adolescent obesity)

This full growth program involved over 2,000 participants across multiple Phase 3 trials, setting up Mazdutide’s effect and safety profile with exceptional rigor.

Control Approval Significance:

China NMPA approval represents a watershed moment for several reasons:

1. First-in-Class Validation: Mazdutide is the world’s first dual GCG/GLP-1 agonist to get control approval for any sign, validating this novel mechanism
2. Competitive Landscape: Approval positions Mazdutide alongside tirzepatide and ahead of investigational triple agonists like retatrutide
3. Clinical Evidence Standard: The approval was based on multiple Phase 3 trials with robust effect and safety data, setting a high bar for future dual agonists
4. Market Access: Approval lets commercial supply in China, the world’s largest obesity market with 500+ million adults with overweight/obesity
5. Research Validation: Control approval provides confidence for researchers that the mechanism is sound and the safety profile is acceptable

Mazdutide vs Other Dual Agonists:

While Mazdutide is the first approved dual GCG/GLP-1 agonist, other dual agonists exist with different receptor mixes:

• Tirzepatide (Mounjaro/Zepbound): Dual GIP/GLP-1 agonist, FDA approved 2022, 22.5% weight loss
• Mazdutide (IBI362): Dual GCG/GLP-1 agonist, China NMPA approved 2025, 20.1% weight loss
• Cotadutide: Dual GCG/GLP-1 agonist, investigational, Phase 2
• Retatrutide: Triple GLP-1/GIP/GCG agonist, investigational, Phase 3, 24.2% weight loss possible

Each dual agonist offers unique benefits based on its receptor mix. Mazdutide’s GCG/GLP-1 mix mainly targets hepatic body function and energy output, making it very valuable for research on liver fat, body syndrome, and obesity with body comorbidities.

Molecular Structure and Dual Mechanism of Action

Mazdutide’s effectiveness stems from its advanced cell-level architecture and unique dual mechanism of action. Grasp these fundamentals is crucial for researchers designing experimental protocols and interpreting results.

Chemical Structure:

Mazdutide (IBI362/LY3305677) is a synthetic peptide analog of mammalian oxyntomodulin with strategic changes:

• Peptide Length: 37 amino acids (similar to native OXM)
• Cell-level Weight: About 4,500 Da
• Key Changes:
  • Amino acid substitutions at positions key for DPP-4 resistance
  • Fatty acid chain attachment for albumin binding (extended half-life)
  • Optimized sequence for balanced GCG/GLP-1 receptor affinity
• Shelf life Features: Protected against enzymatic breakdown, letting once-weekly dosing
• Solubility: Highly soluble in aqueous solutions, suitable for under-skin injection

Receptor Binding Profile:

Mazdutide shows balanced dual agonist activity:

• GLP-1 Receptor (GLP-1R): High affinity binding, full agonist activity
• Glucagon Receptor (GCGR): Moderate-high affinity binding, full agonist activity
• Receptor Balance: About 1:1 to 2:1 GLP-1R:GCGR start ratio (optimized to prevent hyperglycemia)
• Selectivity: Minimal activity at other receptors (GIP, GLP-2, etc.)

This balanced start is key—too much glucagon activity causes hyperglycemia, while too much GLP-1 activity limits the body benefits of glucagon. Mazdutide’s optimized structure achieves the ideal balance.

GLP-1 Receptor Pathway:

When Mazdutide binds to GLP-1 receptors, it starts a cascade of beneficial effects:

Pancreatic Effects:

• Beta Cells: Enhanced glucose-dependent insulin secretion (only when blood glucose is elevated)
• Alpha Cells: Suppressed glucagon secretion in fed state
• Islet Preservation: Possible beta cell protective effects (saw with GLP-1 agonists)

Central Nervous System Effects:

• Hypothalamus: Start of POMC neurons in arcuate nucleus, suppressing appetite
• Brainstem: Start of area postrema and nucleus tractus solitarius, enhancing satiety signals
• Reward Pathways: Tuning of mesolimbic dopamine system, reducing food reward and cravings

Gut Effects:

• Gastric Emptying: Delayed emptying, prolonging satiety after meals
• Gut Motility: Slowed transit, enhancing nutrient absorption time
• Gut Hormones: Tuning of other incretin and satiety hormones

Heart Effects:

• Endothelial Function: Improved endothelial function and reduced swelling
• Blood Pressure: Modest reductions in systolic and diastolic pressure
• Cardiac Protection: Possible cardioprotective effects (saw with GLP-1 agonists)

Glucagon Receptor Pathway:

Mazdutide’s glucagon receptor start provides paired body benefits:

Hepatic Effects:

• Lipolysis: Enhanced breakdown of hepatic fat stores
• Fat Synthesis: Reduced de novo lipogenesis
• Fat Oxidation: Increased beta-oxidation of fatty acids
• Glucose Production: Increased hepatic glucose production (balanced by GLP-1 effects)
• Insulin Response: Improved hepatic insulin response

Body Effects:

• Energy Output: Increased resting energy output and thermogenesis
• Fat Oxidation: Enhanced whole-body fat oxidation
• Lipolysis: Increased adipose tissue lipolysis
• Brown Adipose Tissue: Possible start of brown fat thermogenesis

Heart Effects:

• Cardiac Function: Positive inotropic effects (increased contractility)
• Body Flexibility: Enhanced power to switch between fuel sources

Combined Dual Mechanism:

The true innovation of Mazdutide lies in how these two pathways interact:

1. Weight Loss Synergy: GLP-1 reduces caloric intake while glucagon increases energy output, creating a powerful energy deficit
2. Glucose Homeostasis: GLP-1’s insulin-enhancing and glucagon-suppressing effects counterbalance glucagon receptor’s glucose-raising effects, keeping glycemic control
3. Hepatic Fat Body function: Glucagon’s lipolytic effects are enhanced by GLP-1’s insulin-sensitizing effects, creating superior liver fat reduction
4. Body Flexibility: The mix enhances the body’s power to use both glucose and fat for energy
5. Heart Benefits: Both pathways add to heart gains through paired mechanisms

Pharmacokinetics:

Grasp Mazdutide’s pharmacokinetic profile helps researchers optimize dosing protocols:

• Absorption: Rapid absorption after under-skin injection, Tmax ~24-48 hours
• Distribution: Albumin binding extends half-life and provides sustained exposure
• Half-Life: About 5-7 days, letting once-weekly dosing
• Body function: Proteolytic breakdown, no hepatic body function needed
• Excretion: Renal elimination of metabolites
• Steady State: Achieved after 4-5 weeks of weekly dosing
• Buildup: Minimal buildup with weekly dosing

Pharmacodynamics:

Mazdutide’s effects on key body parameters:

• Weight Loss: Progressive reduction over 24-48 weeks, plateau around 48 weeks
• Appetite Suppression: Onset within days, sustained throughout treatment
• Glycemic Control: Gains within 2-4 weeks in diabetics
• Liver Fat: Major reductions by 12-24 weeks
• Lipid Profile: Gains by 12-24 weeks
• Blood Pressure: Reductions by 12-24 weeks

Dose-Response Relationship:

Clinical trials set up clear dose-response relationships:

• 3mg Weekly: Modest weight loss (~8-10%), good tolerability
• 4.5mg Weekly: Moderate weight loss (~12-14%), acceptable tolerability
• 6mg Weekly: Large weight loss (~14-15%), standard approved dose
• 9mg Weekly: Maximum weight loss (~20%), approved for moderate-severe obesity

Higher doses provide greater effect but with increased GI side effects. The 6mg dose represents the best balance for most patients, while 9mg is reserved for those with more severe obesity.

Clinical Evidence: Comprehensive Phase 3 Trial Results

Mazdutide’s approval is supported by an extensive clinical growth program comprising seven Phase 3 trials with over 2,000 participants. This section synthesizes key findings from these pivotal studies.

GLORY-1 Trial: Pivotal Weight Loss Study

GLORY-1 served as the main basis for Mazdutide’s NMPA approval for chronic weight care.

Study Design:

• Population: Chinese adults with overweight (BMI ≥24 kg/m²) or obesity (BMI ≥28 kg/m²)
• Sample Size: 400+ participants
• Duration: 48 weeks
• Arms: Mazdutide 4mg, Mazdutide 6mg, Placebo
• Main Endpoint: Percentage body weight change from baseline at weeks 32 and 48
• Key Second Endpoints: Proportion achieving ≥5%, ≥10%, ≥15% weight loss; waist circumference; liver fat content

Main Results (48 weeks):

Weight Loss Effect:

• Mazdutide 6mg: -14.8% mean weight loss
• Mazdutide 4mg: -12.0% mean weight loss
• Placebo: -0.5% mean weight loss
• Statistical Significance: Both doses highly major vs placebo (p<0.001)

Weight Loss Responders:

• ≥5% Weight Loss: 82.8% (6mg), 73.5% (4mg), 11.5% (placebo)
• ≥10% Weight Loss: 65.2% (6mg), 54.3% (4mg), 4.2% (placebo)
• ≥15% Weight Loss: 50.6% (6mg), 37.0% (4mg), 2.1% (placebo)

Body Makeup:

• Waist Circumference: -11.0cm (6mg), -9.5cm (4mg), -1.5cm (placebo)
• Visceral Fat: Major reductions in both mazdutide groups

Liver Fat Content (participants with baseline ≥10%):

• Mazdutide 6mg: -80.24% reduction
• Mazdutide 4mg: -65.85% reduction
• Placebo: -5.27% reduction

GLORY-2 Trial: Moderate-Severe Obesity Study

GLORY-2 tested the higher 9mg dose in participants with more severe obesity.

Study Design:

• Population: Chinese adults with moderate-severe obesity (BMI ≥28 kg/m²)
• Sample Size: 300+ participants
• Duration: 48 weeks
• Arms: Mazdutide 9mg, Placebo
• Focus: Maximum effect in severe obesity population

Key Results:

• Weight Loss: 20.1% mean weight loss with 9mg dose
• Responders: >85% achieved ≥5% weight loss, >60% achieved ≥15% weight loss
• Body Benefits: Full gains in all cardiometabolic parameters
• Safety: Acceptable tolerability profile despite higher dose

This 20.1% weight loss represents one of the highest effect rates achieved by any approved weight loss medication, positioning Mazdutide competitively with the most advanced therapies.

DREAMS-1 Trial: Type 2 Diabetes Study

DREAMS-1 assessed Mazdutide in treatment-naive type 2 diabetes patients.

Study Design:

• Population: Chinese adults with untreated type 2 diabetes
• Duration: 24 weeks
• Arms: Mazdutide 3mg, 4.5mg, 6mg, Placebo
• Main Endpoint: HbA1c reduction from baseline

Key Results:

• HbA1c Reduction: -1.27% (dose-dependent)
• Fasting Glucose: -1.73 mmol/L reduction
• Weight Loss: Major weight loss in all mazdutide groups
• Beta Cell Function: Gains in HOMA-β
• Insulin Response: Gains in HOMA-IR

DREAMS-2 Trial: Head-to-Head vs Dulaglutide

DREAMS-2 compared Mazdutide directly to dulaglutide (a GLP-1 agonist) in type 2 diabetes.

Study Design:

• Population: Chinese adults with type 2 diabetes inadequately controlled on oral drugs
• Duration: 24 weeks
• Arms: Mazdutide 6mg, Dulaglutide 1.5mg
• Objective: Show superiority over standard GLP-1 therapy

Key Results:

• HbA1c Reduction: Mazdutide superior to dulaglutide
• Weight Loss: Mazdutide achieved greatly greater weight loss than dulaglutide
• Body Benefits: Superior gains in lipids, liver enzymes, and other body parameters
• Conclusion: Dual GCG/GLP-1 agonism superior to GLP-1 alone

DREAMS-3 Trial: Head-to-Head vs Semaglutide

DREAMS-3 compared Mazdutide to semaglutide (now the leading GLP-1 agonist) in diabetic patients with obesity.

Study Design:

• Population: Chinese adults with type 2 diabetes and obesity
• Duration: 24 weeks
• Arms: Mazdutide 6mg, Semaglutide 1.0mg
• Objective: Show competitive effect vs market leader

Key Results:

• Weight Loss: Mazdutide achieved comparable or superior weight loss to semaglutide
• HbA1c Reduction: Similar glycemic control between groups
• Liver Fat: Mazdutide showed superior liver fat reduction (due to GCG start)
• Body Profile: Mazdutide showed benefits in hepatic and body parameters

This head-to-head comparison validates Mazdutide’s competitive positioning against the current gold standard.

Meta-Test of Mazdutide Trials:

A systematic review and meta-test published in Frontiers in Endocrinology (2024) synthesized data from seven RCTs involving 680 participants:

Overall Effect:

• Mean Weight Loss: -6.22% (95% CI: -8.02% to -4.41%)
• Heterogeneity: High (I² = 90%), reflecting dose and population differences

Subgroup Test:

• Non-Diabetics: -8.44% weight loss (greater than diabetics)
• Diabetics: -3.55% weight loss
• 24-Week Duration: -10.47% weight loss (greater than shorter durations)
• 12-Week Duration: -5.21% weight loss

Cardiometabolic Benefits:

• Systolic BP: -7.57 mmHg
• Diastolic BP: -2.98 mmHg
• Total Cholesterol: -16.82%
• LDL: -17.07%
• Triglycerides: -43.29%
• HDL: -7.54% (modest reduction)

Glycemic Control (Diabetics):

• HbA1c: -1.27%
• Fasting Glucose: -1.73 mmol/L

Safety Profile:

• Nausea: 4.22x higher risk vs placebo (most common side effect)
• Vomiting: 4.91x higher risk vs placebo
• Decreased Appetite: 2.30x higher risk vs placebo
• Serious Adverse Events: Rare, mostly unrelated to study drug
• Discontinuation: Low rates, showing good tolerability

Publication in High-Impact Journals:

Mazdutide’s clinical results have been published in prestigious peer-reviewed journals:

• Nature (2024): Two back-to-back publications of DREAMS-1 and DREAMS-2 Phase 3 results
• New England Journal of Medicine (2024): GLORY-1 Phase 3 results
• Lancet Sub-journals: Multiple publications on mechanism and effect
• Frontiers in Endocrinology (2024): Systematic review and meta-test

This publication record in top-tier journals validates the scientific rigor and clinical significance of Mazdutide’s growth program.

Ongoing Phase 3 Trials:

Several more Phase 3 trials are now ongoing or planned:

• GLORY-3: Mazdutide vs semaglutide in obesity with MAFLD (body-linked fatty liver disease)
• GLORY-OSA: Mazdutide in obstructive sleep apnea with obesity
• Adolescent Obesity Trial: Phase 1b/3 in adolescents with obesity
• MASH Trial: Body dysfunction-linked steatohepatitis
• HFpEF Trial: Heart failure with preserved ejection fraction

These ongoing trials will expand Mazdutide’s evidence base and possibly support more signs.

Comprehensive Dosing Protocols for Research Applications

Proper dosing represents a key factor in Mazdutide research success. The peptide’s effects are highly dose-dependent, and different uses need distinct dosing strategies. This section provides evidence-based protocols based on Phase 3 clinical trials.

China NMPA Approved Dosing (Weight Care):

The approved protocol serves as the foundation for Mazdutide dosing:

Standard Escalation Protocol:

• Weeks 1-4: 3mg under-skin, once weekly
• Weeks 5-8: 4.5mg under-skin, once weekly
• Weeks 9+: 6mg under-skin, once weekly (maintenance)

Other High-Dose Protocol (Moderate-Severe Obesity):

• Weeks 1-4: 3mg under-skin, once weekly
• Weeks 5-8: 4.5mg under-skin, once weekly
• Weeks 9-12: 6mg under-skin, once weekly
• Weeks 13+: 9mg under-skin, once weekly (maintenance)

Rationale for Escalation:

• Gradual dose escalation minimizes GI side effects (nausea, vomiting)
• Allows tolerance growth to GLP-1 effects
• Optimizes adherence and completion rates
• Follows proven protocol from Phase 3 trials

Weight Loss Research Protocol:

For studies examining weight loss effect:

• Population: Adults with BMI ≥24 kg/m² (overweight) or ≥28 kg/m² (obesity)
• Dose: 6mg weekly (standard) or 9mg weekly (severe obesity)
• Escalation: Follow standard 3mg → 4.5mg → 6mg (or 9mg) protocol
• Duration: Minimum 24 weeks, best 48 weeks for maximum effect
• Assessment: Weekly weight, monthly body makeup, quarterly body parameters
• Lifestyle: Combine with reduced-calorie diet and increased physical activity

Type 2 Diabetes Research Protocol:

For studies examining glycemic control:

• Population: Adults with type 2 diabetes (HbA1c 7.0-10.5%)
• Dose: 3mg, 4.5mg, or 6mg weekly (dose-dependent effect)
• Escalation: Standard protocol
• Duration: Minimum 24 weeks for HbA1c assessment
• Assessment: HbA1c at baseline, 12 weeks, 24 weeks; fasting glucose weekly
• Concomitant Therapy: Can be used with metformin, SGLT2 inhibitors; avoid sulfonylureas/insulin first

Liver Fat Research Protocol:

For studies examining hepatic steatosis:

• Population: Adults with MAFLD or NASH (liver fat content ≥10%)
• Dose: 6mg weekly (best for liver fat reduction)
• Duration: Minimum 24 weeks, best 48 weeks
• Assessment: MRI-PDFF or FibroScan at baseline, 24 weeks, 48 weeks
• Biomarkers: ALT, AST, GGT, liver enzymes monthly
• Rationale: GCG start mainly targets hepatic fat body function

Mixing Instructions:

Mazdutide is supplied as freeze-dried powder needing mixing:

Standard Mixing (for 3-6mg doses):

1. Remove flip-top cap from Mazdutide vial and wipe rubber stopper with alcohol swab
2. Remove cap from sterile water vial and wipe rubber stopper with alcohol
3. Draw 2mL of sterile water into sterile syringe
4. Inject water slowly into Mazdutide vial, aiming at vial wall (not directly at powder)
5. Gently swirl or tilt vial to dissolve powder (do not shake vigorously)
6. Refrigerate for 2-4 hours or overnight until completely dissolved
7. Store mixed solution at 2-8°C (refrigerated) for up to 30 days

Level: 10mg vial + 2mL water = 5mg/mL

Dosage Calculations:

For a 10mg vial mixed with 2mL sterile water (5mg/mL):

• 3mg dose: 0.6mL = 60 units on 100-unit insulin syringe
• 4.5mg dose: 0.9mL = 90 units on 100-unit insulin syringe
• 6mg dose: 1.2mL = needs two vials or higher level mixing
• 9mg dose: 1.8mL = needs two vials or higher level mixing

Other High-Level Mixing (for 6-9mg doses):

For higher doses, use less water for higher level:

• 10mg vial + 1mL water = 10mg/mL
• 6mg dose: 0.6mL = 60 units
• 9mg dose: 0.9mL = 90 units

Use Technique:

Proper injection technique ensures best absorption:

1. Syringe Selection: Use insulin syringes (0.5mL or 1mL with 29-31 gauge needles)
2. Injection Site: Abdomen (2 inches from navel), front/outer thigh, or upper arm
3. Site Preparation: Clean injection site with alcohol swab, allow to dry
4. Injection Method:
   • Pinch skin to create fold
   • Insert needle at 90-degree angle (perpendicular to skin)
   • Inject slowly over 5-10 seconds
   • Remove needle and apply gentle pressure (do not rub)
5. Site Rotation: Rotate injection sites weekly to prevent tissue irritation
6. Disposal: Dispose of needles properly in sharps container

Timing Tuning:

Maximizing Mazdutide effectiveness needs proper timing:

• Day of Week: Choose consistent day (e.g., every Monday)
• Time of Day: Can be gave any time, with or without food
• Consistency: Keep same day each week for steady-state levels
• Missed Dose: If <3 days late, take immediately; if >3 days late, skip and resume next scheduled dose
• Flexibility: Can shift injection day by ±2 days if needed

Food and Alcohol Factors:

• Food: Mazdutide can be taken with or without food (absorption not greatly affected)
• GI Tolerability: Some users prefer taking on empty stomach to reduce nausea
• Alcohol: No specific interaction, but moderation advised as alcohol can affect weight loss
• Hydration: Keep good hydration, especially during first weeks

Dose Titration Strategy:

For subjects new to Mazdutide or GLP-1 agonists:

Week 1-4: Start at 3mg to assess tolerance Week 5-8: Increase to 4.5mg if well-tolerated Week 9-12: Increase to 6mg (standard maintenance) Week 13+: Consider 9mg if severe obesity and good tolerability

Special Population Factors:

• Elderly Subjects: Start with standard 3mg, track closely for tolerability
• Renal Impairment: No dose adjustment needed (peptide body function, not renal)
• Hepatic Impairment: Use with caution, track liver enzymes
• Diabetics: May need to reduce other diabetes drugs to prevent hypoglycemia
• Non-Diabetics: Standard dosing, track for hypoglycemia if fasting

Dosing Frequency Rules:

• Standard: Once weekly, same day each week
• Minimum Interval: 5 days between doses (if dose adjustment needed)
• Maximum Frequency: Do not exceed once weekly dosing
• Long-term Use: Can be continued for 48+ weeks based on clinical trials
• Washout: If discontinuing, effects gradually diminish over 2-4 weeks

Storage and Handling:

• Freeze-dried Powder: Store at -20°C (freezer) for up to 2 years
• Mixed Solution: Store at 2-8°C (refrigerator) for up to 30 days
• Protection: Keep away from light, heat, and repeated freeze-thaw cycles
• Sterile Technique: Use proper aseptic technique to prevent contamination
• Visual Inspection: Discard if solution appears cloudy, discolored, or contains particles

Strategic Stacking Protocols and Peptide Combinations

While Mazdutide shows major effects as monotherapy, strategic mixes with paired compounds can enhance specific research outcomes. This section explores evidence-based stacking protocols.

Mazdutide + Semaglutide or Tirzepatide:

Rationale: Combining dual agonist with single or dual agonist for maximum receptor start

IMPORTANT NOTE: This mix is experimental and not clinically validated. Use extreme caution.

Theoretical Protocol:

• Mazdutide: 3-6mg weekly
• Semaglutide: 0.5-1.0mg weekly OR Tirzepatide: 5-10mg weekly
• Tracking: Close tracking of GI side effects, blood glucose, heart rate

Factors:

• Additive GI side effects likely
• Possible for too much weight loss
• Hypoglycemia risk in diabetics
• Not recommended without medical supervision

Mazdutide + Retatrutide:

Rationale: Combining dual agonist with triple agonist (experimental)

IMPORTANT NOTE: This is highly experimental and not recommended. Both are potent multi-receptor agonists.

Factors:

• Overlapping mechanisms (both start GCG and GLP-1)
• Too much receptor start likely
• Unpredictable side effects
• Not recommended for research use

Mazdutide + Tesamorelin:

Rationale: Combining weight loss with growth hormone for body makeup

Protocol:

• Mazdutide: 6mg weekly for weight loss
• Tesamorelin: 2mg daily for visceral fat reduction and lean mass preservation
• Duration: 24-48 weeks

Combined Effects:

• Enhanced visceral fat reduction (both target visceral adiposity)
• Lean mass preservation during weight loss (GH effect)
• Improved body profile
• Better body makeup outcomes

Mazdutide + BPC-157:

Rationale: Weight loss with tissue repair and gut health support

Protocol:

• Mazdutide: 6mg weekly
• BPC-157: 250-500mcg twice daily
• Duration: 24 weeks

Uses:

• Supporting gut health during GI side effects
• Tissue repair during weight loss
• Possible body benefits from BPC-157

Mazdutide + Ipamorelin or Sermorelin:

Rationale: Weight loss with GH secretagogue for lean mass preservation

Protocol:

• Mazdutide: 6mg weekly
• Ipamorelin: 200-300mcg twice daily OR Sermorelin: 200-300mcg daily
• Duration: 24-48 weeks

Benefits:

• Lean mass preservation during weight loss
• Enhanced fat loss
• Improved body makeup
• Better body outcomes

Important Stacking Factors:

1. Side Effect Care:

• Combining peptides increases complexity of side effect attribution
• Introduce peptides sequentially when possible
• Set up baseline response to each compound before combining
• Track for additive or combined side effects

2. Dose Adjustments:

• Consider reducing personal doses by 25-50% when first combining
• Titrate upward based on response and tolerability
• Some mixes may allow lower Mazdutide doses while keeping effect

3. Injection Site Care:

• Multiple injections need careful site rotation
• Use different anatomical areas for different peptides when possible
• Track for injection site reactions or tissue irritation

4. Timing Tuning:

• Mazdutide: Once weekly, any day
• Daily peptides: Consistent timing each day
• Space different peptides by several hours when possible

5. Research Records:

• Keep detailed records of all peptides, doses, timing, and effects
• Document any interactions or unexpected responses
• Track effect of mix vs personal compounds

6. Safety Tracking:

• Regular weight and body makeup assessment
• Blood glucose tracking (especially in diabetics)
• Heart parameter assessment (heart rate, blood pressure)
• Liver function tests (Mazdutide affects hepatic body function)
• Lipid panels
• Watch for signs of too much weight loss or malnutrition

7. Control Compliance:

• Ensure all peptides used in mixes are approved for research
• Follow institutional rules for multi-compound protocols
• Keep proper records for research oversight

Mazdutide vs Tirzepatide vs Retatrutide: Comprehensive Comparison

Grasp how Mazdutide compares to other advanced weight loss peptides helps researchers select the best compound for specific research objectives.

Receptor Start Profiles:

Mazdutide (Dual GCG/GLP-1 Agonist):

• GLP-1 Receptor: +++
• Glucagon Receptor: +++
• GIP Receptor: –
• Mechanism Focus: Appetite suppression + energy output + hepatic fat body function

Tirzepatide (Dual GIP/GLP-1 Agonist):

• GLP-1 Receptor: +++
• GIP Receptor: +++
• Glucagon Receptor: –
• Mechanism Focus: Appetite suppression + insulin response + adipose tissue body function

Retatrutide (Triple GLP-1/GIP/GCG Agonist):

• GLP-1 Receptor: +++
• GIP Receptor: ++
• Glucagon Receptor: ++
• Mechanism Focus: Full multi-pathway start

Clinical Effect Comparison:

Weight Loss:

• Mazdutide: 14.8% (6mg), 20.1% (9mg) at 48 weeks
• Tirzepatide: 15.0% (10mg), 22.5% (15mg) at 72 weeks
• Retatrutide: 24.2% (12mg) at 48 weeks (Phase 2 data)

Body Benefits:

• Mazdutide: Superior liver fat reduction (65-80%), strong lipid gains
• Tirzepatide: Superior insulin response, excellent glycemic control
• Retatrutide: Full body gains across all parameters

Control Status:

• Mazdutide: China NMPA approved (2025) for weight care
• Tirzepatide: FDA approved (2022) for diabetes and obesity
• Retatrutide: Investigational (Phase 3)

Dosing and Use:

Mazdutide:

• Dose Range: 3-9mg weekly
• Escalation: 3mg → 4.5mg → 6mg (or 9mg)
• Duration to Max Effect: 48 weeks
• Convenience: Once weekly injection

Tirzepatide:

• Dose Range: 5-15mg weekly
• Escalation: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
• Duration to Max Effect: 72 weeks
• Convenience: Once weekly injection

Retatrutide:

• Dose Range: 4-12mg weekly (Phase 2)
• Escalation: Gradual escalation protocol
• Duration to Max Effect: 48 weeks (Phase 2 data)
• Convenience: Once weekly injection

Side Effect Profiles:

Mazdutide:

• Common: Nausea (most common), decreased appetite, vomiting, diarrhea
• Heart: Increased heart rate (5-17 bpm)
• Serious: Rare, mostly unrelated to drug
• Tolerability: Good, low discontinuation rates

Tirzepatide:

• Common: Nausea, diarrhea, vomiting, constipation, decreased appetite
• Heart: Increased heart rate (modest)
• Serious: Rare, pancreatitis risk (class effect)
• Tolerability: Good, set up safety profile

Retatrutide:

• Common: Nausea, vomiting, diarrhea (higher rates than dual agonists)
• Heart: Increased heart rate (more pronounced)
• Serious: Limited data (Phase 2/3)
• Tolerability: Acceptable but higher GI side effects

Mechanism-Specific Benefits:

Mazdutide Benefits:

• Superior liver fat reduction (GCG start)
• Increased energy output (GCG start)
• Enhanced hepatic insulin response
• Proven safety with control approval
• Lower cost possible (simpler manufacturing)

Tirzepatide Benefits:

• FDA approved with extensive safety data
• Superior insulin response (GIP start)
• Excellent glycemic control in diabetes
• Set up clinical use and prescribing experience
• Full heart outcome data

Retatrutide Benefits:

• Highest weight loss possible (triple mechanism)
• Full body gains
• Novel mechanism for research
• Possible for superior effect
• Addresses multiple pathways simultaneously

Research Use Recommendations:

Choose Mazdutide for:

• Liver fat and MAFLD/NASH research
• Energy output studies
• Hepatic body function research
• Studies needing control-approved mechanism
• Cost-sensitive research projects
• Research in Asian populations (approved in China)

Choose Tirzepatide for:

• Diabetes and obesity research
• Insulin response studies
• Heart outcome research
• Studies needing FDA-approved compound
• Research with set up safety data
• Clinical translation research

Choose Retatrutide for:

• Maximum effect research
• Novel mechanism exploration
• Full body research
• Cutting-edge obesity research
• Studies exploring triple agonism
• Research not needing control approval

Head-to-Head Comparison Summary:

Feature	Mazdutide	Tirzepatide	Retatrutide
Mechanism	GCG/GLP-1	GIP/GLP-1	GLP-1/GIP/GCG
Weight Loss	20.1%	22.5%	24.2%
Approval	China NMPA	FDA	Investigational
Liver Fat	Superior	Good	Excellent
Diabetes	Excellent	Superior	Excellent
Safety Data	Extensive	Most Extensive	Limited
Cost	Moderate	High	Unknown
Supply	Research	Clinical + Research	Research Only

Conclusion:

All three peptides represent next-generation weight loss therapies superior to single-receptor agonists. Mazdutide offers unique benefits in liver body function and control approval, Tirzepatide provides the most set up safety and effect data, and Retatrutide offers the highest possible effect through triple agonism. Researchers should select based on specific research objectives, control requirements, and desired outcomes.

Safety Profile, Side Effects, and Risk Mitigation

Grasp Mazdutide’s safety profile is essential for responsible research conduct. While the peptide has China NMPA approval with well-characterized safety data from Phase 3 trials, researchers must remain aware of possible adverse effects.

Common Side Effects (Frequency >10%):

Nausea:

• Most frequent side effect in clinical trials
• Often occurs during dose escalation
• Usually transient, resolving within days to weeks
• Severity decreases with continued use (tolerance growth)

Mitigation Strategies:

• Follow gradual dose escalation protocol (3mg → 4.5mg → 6mg)
• Take with small amounts of food if needed
• Use anti-nausea medication (ginger, vitamin B6, ondansetron) if severe
• Stay well-hydrated
• Avoid high-fat meals which may worsen nausea

Decreased Appetite:

• Expected pharmacological effect (treatment benefit)
• Can be pronounced, especially at higher doses
• May lead to inadequate nutrition if severe

Care:

• Track nutritional intake and body weight
• Ensure enough protein consumption
• Consider nutritional use if needed
• Reduce dose if appetite suppression is too much

Vomiting:

• Less common than nausea but can occur
• Usually during first weeks or after dose escalation
• Often resolves with continued use

Care:

• Anti-emetic medication if needed
• Hydration maintenance
• Consider slower dose escalation
• Temporary dose reduction if severe

Diarrhea:

• More common in diabetic participants
• Related to GLP-1 effects on GI motility
• Usually mild to moderate

Care:

• Enough hydration
• Dietary changes (avoid high-fat foods)
• Anti-diarrheal medication if needed
• Track for dehydration

Uncommon Side Effects (Frequency 1-10%):

Increased Heart Rate:

• Saw in all participants on Mazdutide
• Average increase: 5-17 beats per minute
• Related to glucagon receptor start
• No increased cardiac events in trials

Tracking:

• Baseline heart rate measurement
• Periodic heart rate tracking
• Heart assessment if major increase
• Consider dose reduction if heart rate >100 bpm at rest

Constipation:

• Can occur due to GLP-1 effects on GI motility
• Usually mild

Care:

• Enough hydration
• Dietary fiber
• Physical activity
• Stool softeners if needed

Injection Site Reactions:

• Mild pain, redness, or itching at injection site
• Usually resolves within hours

Care:

• Rotate injection sites
• Proper injection technique
• Ice use if swelling occurs
• Ensure solution is at room heat before injecting

Rare but Notable Side Effects:

Hypoglycemia:

• Risk mainly in diabetics on other glucose-lowering drugs
• Rare in non-diabetics
• GLP-1 effects are glucose-dependent (lower risk than insulin/sulfonylureas)

Prevention:

• Reduce other diabetes drugs when starting Mazdutide
• Track blood glucose regularly
• Educate subjects on hypoglycemia recognition
• Adjust concomitant drugs as needed

Pancreatitis:

• Theoretical risk with GLP-1 agonists (class effect)
• No increased incidence in Mazdutide trials
• Symptoms: Severe abdominal pain, nausea, vomiting

Care:

• Exclude subjects with history of pancreatitis
• Track for symptoms
• Discontinue if pancreatitis suspected
• Seek immediate medical attention if symptoms occur

Gallbladder Disease:

• Rapid weight loss can increase gallstone risk
• Track for symptoms (right upper quadrant pain)

Prevention:

• Gradual weight loss (not too rapid)
• Enough hydration
• Track for symptoms
• Ultrasound if symptoms develop

Heart Effects:

Blood Pressure Changes:

• Often decreases blood pressure (beneficial)
• Average reductions: -7.6 mmHg systolic, -3.0 mmHg diastolic
• Related to weight loss and body gains

Heart Rate Increase:

• Consistent finding across all participants
• Average increase: 5-17 bpm
• Related to glucagon receptor start
• No increased cardiac events in trials

Tracking Protocol:

• Baseline blood pressure and heart rate
• Monthly tracking during treatment
• Heart assessment if major changes
• Consider dose reduction if heart rate >100 bpm or BP changes concerning

Contraindications:

Mazdutide should not be used in subjects with:

1. Personal or Family History of Medullary Thyroid Carcinoma (MTC): GLP-1 agonists increase C-cell tumors in rodents (relevance to humans unclear)
2. Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2): Increased MTC risk
3. Pregnancy or Breastfeeding: No safety data in these populations
4. Age <18 Years: Limited data (Phase 1b trial in adolescents ongoing)
5. Severe Gut Disease: May worsen symptoms
6. History of Pancreatitis: Theoretical increased risk

Relative Contraindications (Use with Caution):

• History of gallbladder disease
• Severe renal impairment (limited data)
• Severe hepatic impairment (track liver enzymes)
• Heart disease (track heart rate)
• Diabetic retinopathy (rapid glucose lowering may worsen)

Drug Interactions:

Oral Drugs:

• Mazdutide delays gastric emptying, possibly affecting oral medication absorption
• Take oral drugs 1 hour before or 4 hours after Mazdutide injection
• Track effectiveness of time-sensitive drugs

Insulin and Sulfonylureas:

• Increased hypoglycemia risk when combined
• Reduce doses of these drugs when starting Mazdutide
• Track blood glucose closely

Other GLP-1 Agonists:

• Do not combine with other GLP-1 agonists (additive effects, increased side effects)

Long-Term Safety Factors:

Phase 3 Trial Data (Up to 48 Weeks):

• No buildup of adverse effects with ongoing use
• Side effects remain transient with each dose
• No evidence of organ toxicity
• Safety profile consistent across study duration

Areas Needing Further Research:

• Effects of very long-term use (>1 year)
• Safety in special populations (elderly, multiple comorbidities)
• Long-term heart outcomes
• Possible for tolerance or dependence

Quality and Purity Factors:

Peptide quality greatly impacts safety:

• Contaminants: Low-purity peptides may contain bacterial endotoxins, heavy metals, or synthesis byproducts
• Breakdown Products: Improperly stored peptides may degrade into possibly harmful compounds
• Incorrect Sequences: Poor synthesis can result in peptides with wrong amino acid sequences

PrymaLab Quality Assurance:

• 99%+ purity via HPLC
• <1 EU/mg endotoxin levels
• Third-party check
• Proper storage and handling
• Complete records

Safety Tracking Protocol for Research:

Baseline Assessment:

• Medical history and physical review
• Weight, BMI, waist circumference
• Blood pressure and heart rate
• Full body panel
• Lipid panel
• HbA1c (if diabetic)
• Liver function tests
• Thyroid function tests
• Pregnancy test (if applicable)

During Research:

• Weekly weight tracking
• Monthly blood pressure and heart rate
• Monthly side effect assessment
• Quarterly body panels
• Quarterly lipid panels
• HbA1c every 12 weeks (if diabetic)
• Liver function tests every 12 weeks

Follow-Up:

• Post-study assessment of weight and body parameters
• Long-term follow-up for sustained effects
• Records of any persistent effects

Adverse Event Reporting:

• Document all adverse events, regardless of severity
• Report serious adverse events to institutional review board
• Keep detailed records for control compliance
• Add to post-marketing surveillance

Summary:

Mazdutide has a favorable safety profile supported by China NMPA approval and extensive Phase 3 trial data. Most side effects are GI-related, transient, and manageable. The main safety concerns are:

1. GI side effects (nausea, vomiting, diarrhea) – common but usually mild-moderate
2. Increased heart rate – consistent but no increased cardiac events
3. Hypoglycemia risk in diabetics on other drugs
4. Theoretical pancreatitis risk (class effect, not saw in trials)

Proper patient selection, appropriate dosing with gradual escalation, and vigilant tracking minimize risks and ensure safe research conduct.

Quality Assurance: Third-Party Testing and Purity Verification

Research integrity depends fundamentally on peptide quality. PrymaLab’s rigorous quality assurance program ensures every Mazdutide vial meets pharmaceutical-grade standards matching China NMPA approved specifications.

Third-Party Laboratory Testing:

Every batch of PrymaLab Mazdutide undergoes full test by independent, ISO-certified laboratories. This third-party check provides unbiased confirmation of quality.

High-Performance Liquid Chromatography (HPLC):

HPLC represents the gold standard for peptide purity test:

• Method: Separates peptide components based on chemical properties
• Precision: Quantifies target peptide and identifies impurities
• PrymaLab Standard: ≥99% purity by HPLC
• Interpretation: 99% or more of material is correct Mazdutide peptide
• Impurities: <1% consists of minor synthesis byproducts, salts, residual solvents at safe levels

Mass Spectrometry (MS):

Mass spectrometry confirms cell-level identity:

• Purpose: Verifies cell-level weight and amino acid sequence
• Precision: Detects even single amino acid substitutions
• PrymaLab Check: Confirms cell-level weight matching IBI362 specifications
• Quality Control: Ensures peptide is authentic Mazdutide, not related compound or synthesis error

Amino Acid Test:

Quantitative amino acid test provides more check:

• Method: Confirms correct amino acid makeup and ratios
• Purpose: Validates peptide identity and sequence
• Quality Assurance: Detects any amino acid substitutions or deletions

Endotoxin Testing:

Bacterial endotoxins can contaminate peptides during synthesis or handling:

• Method: Limulus Amebocyte Lysate (LAL) assay
• PrymaLab Standard: <1 EU/mg (well below control limit of 5 EU/mg)
• Importance: Prevents fever, swelling, and other adverse effects
• Testing Frequency: Every batch tested before release

Sterility Testing:

While freeze-dried peptides are not sterile products, contamination testing ensures safety:

• Method: Tests for bacterial and fungal contamination
• Purpose: Ensures product safety
• Protection: Mixing with sterile water provides antimicrobial protection during storage

Certificate of Test (COA):

Every PrymaLab Mazdutide buy includes full records:

COA Contents:

1. Batch number and manufacturing date
2. HPLC purity results with chromatogram
3. Mass spectrometry data confirming cell-level weight
4. Amino acid test results
5. Endotoxin test results
6. Sterility test results
7. Storage recommendations
8. Expiration date
9. Handling instructions

Storage and Shelf life:

Proper storage keeps peptide quality throughout shelf life:

Freeze-dried Powder:

• Heat: -20°C (freezer)
• Duration: Up to 2 years
• Protection: Keep away from light and moisture
• Packaging: Sealed vials with desiccant

Mixed Solution:

• Heat: 2-8°C (refrigerator)
• Duration: Up to 30 days
• Protection: Keep away from light
• Sterility: Use sterile technique to prevent contamination
• Shelf life: Track for cloudiness or discoloration

Handling Best Practices:

• Avoid repeated freeze-thaw cycles
• Use aseptic technique when handling
• Do not shake vigorously (gentle swirling only)
• Protect from direct sunlight
• Store in original packaging until use

Visual Inspection:

Before use, inspect peptide vials for quality indicators:

Freeze-dried Powder Should Be:

• White to off-white color
• Fluffy or cake-like texture
• Free from discoloration
• No clumping or unusual appearance

Mixed Solution Should Be:

• Clear and colorless
• Free from particulates
• No cloudiness or precipitation
• No unusual odor

If Any Abnormalities Saw:

• Do not use the product
• Contact vendor immediately
• Document appearance with photos if possible
• Request replacement

Comparison to China NMPA Approved Mazdutide:

PrymaLab Mazdutide meets or exceeds the quality standards of NMPA-approved Mazdutide:

• Purity: 99%+ (matches pharmaceutical grade)
• Testing: Same analytical methods (HPLC, MS)
• Endotoxins: <1 EU/mg (same as approved specification)
• Cell-level Weight: Matches IBI362 specifications
• Sequence: Identical to approved Mazdutide

Quality Assurance Process:

Step 1: Synthesis

• Pharmaceutical-grade synthesis facility
• GMP-compliant manufacturing
• Batch records and traceability

Step 2: In-House Testing

• First purity assessment
• Identity check
• Preliminary quality control

Step 3: Third-Party Check

• Independent laboratory testing
• HPLC, MS, amino acid test
• Endotoxin and sterility testing

Step 4: Records

• Certificate of Test preparation
• Batch record compilation
• Quality release approval

Step 5: Storage and Shipping

• Proper storage conditions kept
• Cold chain care for shipping
• Packaging to protect from damage

Step 6: Customer Support

• COA provided with every order
• Technical support available
• Replacement policy for quality issues

Control Compliance:

PrymaLab keeps compliance with applicable regulations:

• GMP Standards: Good Manufacturing Practices followed
• ISO Certification: Third-party labs are ISO-certified
• Records: Complete batch records kept
• Traceability: Full chain of custody records
• Research Use: Clearly labeled for research purposes only

Why Quality Matters:

Research Integrity:

• Reliable, reproducible results
• Valid scientific conclusions
• Publishable data

Subject Safety:

• Minimizes contamination risks
• Reduces adverse event possible
• Ensures predictable effects

Cost Effectiveness:

• Avoids wasted research resources
• Prevents need to repeat studies
• Maximizes research investment

Professional Reputation:

• Keeps institutional credibility
• Supports grant uses
• Lets collaboration

Purchasing Considerations: Why Choose PrymaLab

The research peptide market contains many vendors with varying quality standards. Selecting a trusted supplier is crucial for Mazdutide research success.

Uncompromising Quality Standards:

PrymaLab keeps pharmaceutical-grade quality standards matching China NMPA approved Mazdutide:

• 99%+ Purity: Exceeds industry norms, verified by HPLC
• Third-Party Testing: Independent laboratory check
• Complete Records: COA with every order
• Batch Consistency: Rigorous quality control ensures consistency
• NMPA-Equivalent Standards: Same quality as approved medication

Transparent Testing Records:

We provide complete transparency in quality check:

• Detailed COAs: HPLC chromatograms, mass spectrometry data, endotoxin results
• Batch Traceability: Full records from synthesis to supply
• Independent Check: Unbiased third-party testing
• Accessible Support: Technical team available to discuss testing data
• Institutional Compliance: Records meets research institution requirements

Competitive Pricing:

Despite premium quality standards, PrymaLab offers exceptional value:

• Mazdutide 10mg: $49 per vial (competitive vs $70-100 elsewhere)
• Volume Discounts: Available for larger orders
• No Hidden Fees: Transparent pricing structure
• Value Proposition: Pharmaceutical-grade quality at research-grade prices
• Cost Per Dose: About $8.17 per 6mg dose (10mg vial = 1.67 doses at 6mg)

Fast, Reliable Shipping:

Research timelines are key, and we deliver:

• Processing Time: Orders ship within 24 hours of payment
• Domestic Supply: 3-5 business days (USA)
• International Shipping: Available to most countries
• Tracking: Provided for all orders
• Packaging: Discreet, professional packaging
• Cold Chain: Proper heat control kept

Secure Payment Options:

Multiple payment methods for convenience and security:

• Credit Cards: Visa, Mastercard, American Express
• Cryptocurrency: Bitcoin, Ethereum (more privacy)
• Bank Transfers: Wire transfer for larger orders
• Digital Platforms: Zelle, CashApp
• Security: SSL encryption protects all transactions
• Privacy: Discreet billing descriptors

Exceptional Customer Support:

Our knowledgeable team provides full support:

• Response Time: Within 24 hours (often much faster)
• Supply: Email, phone, live chat
• Expertise: Staff trained in peptide research uses
• Technical Support: Help with mixing, dosing, protocols
• Order Tracking: Help with shipping questions
• Problem Resolution: Dedicated to customer satisfaction

Educational Resources:

PrymaLab provides full educational content:

• Detailed Product Descriptions: Research uses and mechanisms
• Dosing Protocols: Evidence-based rules from clinical trials
• Mixing Guides: Step-by-step instructions with images
• Safety Data: Side effect care and tracking
• Research Literature: References to published studies
• Comparison Guides: Mazdutide vs other peptides

Institutional Accounts:

We work with research institutions worldwide:

• Volume Pricing: Discounts for institutional orders
• Buy Orders: PO payment options available
• Dedicated Account Care: Personalized service
• Priority Shipping: Expedited supply for institutions
• Custom Records: Tailored to institutional requirements
• Compliance Support: Help with control records

Satisfaction Guarantee:

We stand behind our products with confidence:

• Quality Guarantee: If product doesn’t meet specifications, we’ll replace it
• Response Time: Quality concerns addressed within 24 hours
• Resolution Process: Fair, transparent problem-solving
• Customer First: Your satisfaction is our priority
• Long-term Relationships: We value ongoing partnerships

Control Compliance:

All PrymaLab peptides comply with applicable regulations:

• Research Use Only: Clearly labeled and documented
• Not for Human Consumption: Explicit disclaimers
• Age Check: 21+ requirement enforced
• Professional Use: Intended for qualified researchers
• Records: Proper records kept
• Legal Compliance: Adherence to federal and state laws

Related Research Peptides and Supplies

Full peptide research often needs multiple compounds and supplies. PrymaLab offers a complete range of research peptides and essential materials.

Related Weight Loss Peptides:

Semaglutide 5mg:

• Single GLP-1 receptor agonist
• 15% weight loss effect
• FDA approved mechanism
• Comparison baseline for dual agonists

Tirzepatide 5mg:

• Dual GIP/GLP-1 receptor agonist
• 22.5% weight loss effect
• FDA approved for diabetes and obesity
• Direct competitor to Mazdutide

Retatrutide 5mg:

• Triple GLP-1/GIP/GCG receptor agonist
• 24.2% weight loss possible
• Investigational (Phase 3)
• Next-generation triple agonist

Cagrilintide 5mg:

• Amylin receptor agonist
• Paired to GLP-1 agonists
• CagriSema mix component
• Novel mechanism for weight loss

Growth Hormone Peptides:

Tesamorelin 5mg:

• GHRH analog for visceral fat reduction
• FDA approved mechanism
• Combined with Mazdutide for body makeup
• 15-20% visceral fat reduction

Ipamorelin 5mg:

• Selective GH secretagogue
• Lean mass preservation during weight loss
• Combines well with Mazdutide
• Clean side effect profile

Sermorelin 5mg:

• GHRH analog for natural GH rise
• Supports vitality during weight loss
• Cost-effective GH peptide
• Anti-aging benefits

CJC-1295 5mg:

• Long-acting GHRH analog
• Sustained GH rise
• Body makeup benefits
• Combined with Mazdutide

Healing and Tissue Repair Peptides:

BPC-157 5mg:

• Gastric peptide with healing properties
• Supports gut health during GI side effects
• Tissue repair during weight loss
• Anti-swelling benefits

TB-500 5mg:

• Thymosin beta-4 fragment
• Promotes angiogenesis and tissue repair
• May enhance body health
• Healing support

Essential Research Supplies:

Sterile Water 3mL:

• Sterile water with 0.9% benzyl alcohol
• Essential for peptide mixing
• Provides antimicrobial protection during storage
• Multiple vials recommended for frequent use

Insulin Syringes:

• 0.5mL and 1mL syringes with 29-31 gauge needles
• Precise dosing for peptide use
• Minimal discomfort with small needles
• Proper disposal in sharps container needed

Research Tools:

Peptide Calculator:

• Free online dosing calculator
• Calculates peptide doses and mixing volumes
• Converts between units (mg, mcg, IU)
• Removes dosing errors
• Simplifies protocol planning

Browse Complete Catalog:

Shop All Peptides:

• Complete range of research peptides
• Organized by category and use
• Detailed product descriptions
• Competitive pricing
• Volume discounts available

Frequently Asked Questions (FAQs)

1. What is Mazdutide and how does it work?

Mazdutide (IBI362/LY3305677) is the world’s first approved dual GCG/GLP-1 receptor agonist for chronic weight care. It’s a synthetic mammalian oxyntomodulin analog that simultaneously starts both glucagon receptors (mainly in liver) and GLP-1 receptors (in pancreas, brain, and GI tract). This dual mechanism provides superior weight loss effect by combining GLP-1’s appetite suppression and insulin secretion with glucagon’s energy output increase and hepatic fat body function gain. The balanced start prevents hyperglycemia while maximizing weight loss and body benefits. Mazdutide got China NMPA approval in June 2025 based on Phase 3 trials showing up to 20.1% weight loss with full body gains.

2. How does Mazdutide compare to Tirzepatide and Retatrutide?

Mazdutide (dual GCG/GLP-1), Tirzepatide (dual GIP/GLP-1), and Retatrutide (triple GLP-1/GIP/GCG) represent next-generation weight loss peptides with different receptor mixes. Weight loss: Mazdutide 20.1%, Tirzepatide 22.5%, Retatrutide 24.2%. Approval status: Mazdutide China NMPA approved 2025, Tirzepatide FDA approved 2022, Retatrutide investigational Phase 3. Key differences: Mazdutide emphasizes liver fat body function and energy output (GCG start), Tirzepatide emphasizes insulin response (GIP start), Retatrutide combines all mechanisms. Mazdutide offers unique benefits in hepatic body function research and has control approval validating its mechanism. Choice depends on research objectives, control requirements, and desired body focus.

3. What is the proper dosage for Mazdutide research?

The China NMPA approved protocol uses gradual dose escalation: Weeks 1-4: 3mg weekly, Weeks 5-8: 4.5mg weekly, Weeks 9+: 6mg weekly (standard maintenance). For moderate-severe obesity research, escalate to 9mg weekly after week 12. Use: Under-skin injection, once weekly, any time of day. Mixing: 10mg vial with 2mL sterile water yields 5mg/mL. Dosing calculations: 3mg = 0.6mL (60 units), 4.5mg = 0.9mL (90 units), 6mg = 1.2mL (needs two vials or higher level). Duration: Minimum 24 weeks, best 48 weeks for maximum effect. Gradual escalation minimizes GI side effects and optimizes tolerability. All protocols based on Phase 3 GLORY trials.

4. How do I reconstitute and store Mazdutide?

Reconstitute by adding 2mL sterile water to the 10mg vial. Inject water slowly against the vial wall, then gently swirl (don’t shake) to dissolve. Refrigerate for 2-4 hours until completely dissolved. Store freeze-dried powder at -20°C (freezer) for up to 2 years. Store mixed solution at 2-8°C (refrigerator) for up to 30 days. Protect from light and avoid repeated freeze-thaw cycles. Use sterile technique when handling to prevent contamination. Before use, inspect the solution – it should be clear and colorless with no particles or cloudiness. Discard if any abnormalities saw.

5. What are the most common side effects of Mazdutide?

The most common side effects are gut: nausea (most frequent), decreased appetite, vomiting, and diarrhea (more common in diabetics). These are often mild-moderate, transient, and resolve within days to weeks. Heart effects include increased heart rate (5-17 bpm average) with no increased cardiac events in trials. Other effects include injection site reactions and constipation. Gradual dose escalation (3mg → 4.5mg → 6mg) greatly reduces GI side effects. Most side effects diminish with continued use as tolerance develops. Serious adverse events are rare and mostly unrelated to study drug. The favorable safety profile supported China NMPA approval for chronic weight care.

6. Can Mazdutide be combined with other weight loss peptides?

Combining Mazdutide with other weight loss peptides is experimental and needs extreme caution. Mazdutide + Semaglutide or Tirzepatide: Not recommended due to overlapping GLP-1 start and additive GI side effects. Mazdutide + Retatrutide: Not recommended due to overlapping mechanisms (both start GCG and GLP-1). Mazdutide + Tesamorelin: Possibly combined for body makeup (weight loss + visceral fat reduction + lean mass preservation). Mazdutide + Ipamorelin/Sermorelin: May help preserve lean mass during weight loss. When stacking, start with lower doses (25-50% reduction), introduce sequentially, track closely for side effects, and keep detailed records. Most research should use Mazdutide as monotherapy given its full dual mechanism.

7. How long does it take to see results from Mazdutide?

Results timeline varies by outcome: Weight loss begins within 2-4 weeks, with progressive reduction over 24-48 weeks. Appetite suppression occurs within days of first dose. Glycemic control gains (in diabetics) appear within 2-4 weeks. Liver fat reduction becomes major by 12-24 weeks (65-80% reduction by 48 weeks). Lipid profile gains occur by 12-24 weeks. Blood pressure reductions appear by 12-24 weeks. Maximum weight loss often achieved around 48 weeks. Phase 3 trials showed 14.8% weight loss at 48 weeks (6mg dose) and 20.1% weight loss at 48 weeks (9mg dose). Gradual dose escalation means full treatment dose not reached until week 9, so maximum effects need several months of treatment.

8. Is Mazdutide safe for long-term research?

Mazdutide has favorable long-term safety data from Phase 3 trials extending up to 48 weeks. Studies show no buildup of adverse effects with ongoing use – side effects remain transient with each dose. No evidence of organ toxicity emerged during trials. Safety profile consistent across study duration. China NMPA approval validates safety for chronic weight care. However, data beyond 48 weeks is limited. For extended research: Use regular safety tracking (monthly minimum), track heart parameters (heart rate, blood pressure), assess liver function quarterly, watch for gallbladder disease symptoms, track nutritional status and body makeup, consider periodic washout periods for very long-term studies. The dual GCG/GLP-1 mechanism is well-tolerated with appropriate tracking and dose escalation.

9. What makes PrymaLab’s Mazdutide superior to competitors?

PrymaLab Mazdutide offers: (1) Pharmaceutical-grade 99%+ purity matching China NMPA approved specifications, verified by third-party testing, (2) Complete Certificates of Test with every order including HPLC, mass spectrometry, and endotoxin data, (3) Competitive pricing at $49 per 10mg vial (vs $70-100 elsewhere), (4) Fast shipping within 24 hours of payment, (5) Multiple secure payment options, (6) Exceptional customer support responding within 24 hours, (7) Full educational resources and evidence-based dosing protocols based on Phase 3 GLORY trials, (8) Satisfaction guarantee and quality commitment. Our rigorous quality standards ensure researchers work with the same quality as NMPA-approved medication, providing confidence in research results and control compliance.

10. Who should not use Mazdutide in research?

Exclude subjects with: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pregnancy or breastfeeding, age <18 years (limited data), severe gut disease, history of pancreatitis. Use caution in subjects with: History of gallbladder disease, severe renal or hepatic impairment, heart disease (track heart rate closely), diabetic retinopathy (rapid glucose lowering may worsen), concurrent use of insulin or sulfonylureas (hypoglycemia risk). Always screen subjects carefully, use appropriate tracking protocols, and ensure heart and body health is enough before starting Mazdutide research. The China NMPA approval and extensive Phase 3 trial data provide confidence in safety for appropriate populations under proper medical supervision.

---

6. TECHNICAL SPECIFICATIONS

Chemical Information

• Chemical Name: Mazdutide (IBI362, LY3305677)
• Other Names: IBI362, LY3305677
• Drug Class: Dual GCG/GLP-1 receptor agonist
• Peptide Type: Synthetic mammalian oxyntomodulin (OXM) analog
• Cell-level Weight: About 4,500 Da
• Peptide Length: 37 amino acids
• Structure Type: Modified linear peptide with fatty acid chain
• Purity: ≥99% (HPLC verified)
• Appearance: White to off-white freeze-dried powder
• Solubility: Highly soluble in sterile water, sterile water, or saline

Pharmacological Properties

• Main Targets: GLP-1 Receptor (GLP-1R), Glucagon Receptor (GCGR)
• Receptor Balance: About 1:1 to 2:1 GLP-1R:GCGR start
• Mechanism: Dual agonist – appetite suppression + energy output
• Uptake: High (under-skin injection)
• Tmax: 24-48 hours
• Half-Life: About 5-7 days
• Duration of Action: Once-weekly dosing
• Body function: Proteolytic breakdown
• Excretion: Renal elimination of metabolites

Storage and Handling

• Storage Heat (Freeze-dried): -20°C (freezer)
• Storage Heat (Mixed): 2-8°C (refrigerator)
• Shelf Life (Freeze-dried): 24 months when stored properly
• Shelf Life (Mixed): 30 days when refrigerated
• Light Response: Protect from direct light
• Handling: Use sterile technique; avoid repeated freeze-thaw cycles

Quality Control

• Manufacturing Standard: GMP-compliant facility
• Purity Testing: HPLC, Mass Spectrometry, Amino Acid Test
• Endotoxin Level: <1 EU/mg (LAL assay)
• Sterility: Tested for bacterial and fungal contamination
• Heavy Metals: Below detection limits
• Residual Solvents: Within ICH rules
• Batch Records: Complete traceability

Packaging

• Vial Size: 10mg per vial
• Vial Type: Sterile glass vial with rubber stopper and flip-off cap
• Packaging: Personal vials in protective packaging
• Labeling: Batch number, manufacturing date, expiration date
• Records: Certificate of Test included

Regulatory Status

• China NMPA: Approved for chronic weight care (June 2025)
• FDA Status: Not approved (investigational in US)
• Research Use: Available for research purposes globally
• DEA Schedule: Not a controlled substance

---

7. COMPLIANCE & LEGAL DISCLAIMER

Research Use Only

Mazdutide is sold exclusively as a research chemical for scientific and educational purposes. This product is NOT intended for human consumption, medical use, or any use involving use to humans or animals outside of controlled research settings. While Mazdutide has China NMPA approval for chronic weight care, this research-grade form is intended solely for laboratory research.

Age Restriction

Purchasers must be 21 years of age or older. By buying this product, you confirm that you meet this age requirement and will use the product only for legitimate research purposes.

Professional Use

This product is intended for use by qualified researchers, scientists, and healthcare professionals conducting legitimate research. Proper training in peptide handling, mixing, and research protocols is needed.

Not a Medication

Mazdutide research peptide is not a medication, drug, or treatment agent for personal use. While China’s NMPA has approved mazdutide for specific medical signs, this research-grade product has not been assessed or approved by the FDA for the treatment, cure, or prevention of any disease or medical condition. Any statements about research uses are based on published scientific literature and do not constitute medical claims.

China NMPA Approval Context

Mazdutide got China NMPA approval in June 2025 as the world’s first dual GCG/GLP-1 receptor agonist for chronic weight care in adults with overweight or obesity. This approval validates the peptide’s mechanism of action and safety profile through rigorous Phase 3 clinical trials. However, the research-grade Mazdutide offered by PrymaLab is intended for research purposes only and is not the NMPA-approved form for medical use.

Safety and Liability

Users assume all responsibility for proper handling, storage, and use of this product. PrymaLab is not liable for any adverse effects, injuries, or damages resulting from improper use, misuse, or use outside of controlled research settings. Researchers must use appropriate safety protocols and get necessary institutional approvals before conducting research.

Consultation Requirement

Anyone considering research involving Mazdutide should consult with qualified healthcare professionals, institutional review boards, and control authorities as appropriate. This is very important for research involving human subjects, which needs proper ethical approval and informed consent procedures.

International Regulations

Peptide regulations vary by country. International purchasers are responsible for ensuring compliance with their local laws and regulations about peptide importation and research use. PrymaLab is not responsible for shipments seized by customs or violations of local regulations.

Product Disclaimer

While we keep rigorous quality control standards, PrymaLab makes no warranties about the suitability of this product for any specific research use. Researchers are responsible for validating product performance in their specific experimental systems.

---

8. REFERENCES AND SCIENTIFIC LITERATURE

1. Ji L, Gao L, Jiang H, et al. Safety and effect of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022;54:101691.
2. Ji L, Jiang H, An P, et al. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine. 2021;39:101088.
3. Jiang H, Pang S, Zhang Y, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022;13(1):3613.
4. Zhang B, Cheng Z, Chen J, et al. Effect and safety of mazdutide in chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care. 2024;47:160-168.
5. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14:8042.
6. Nalisa DL, Cuboia N, Dyab E, et al. Effect and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-test of randomized controlled trials. Front Endocrinol. 2024;15:1309118.
7. Innovent Biologics. Mazdutide Gets China NMPA Approval for Chronic Weight Care. Press Release. June 27, 2025.
8. Innovent Biologics. Nature: Two Phase 3 Clinical Results of Mazdutide Published Back-to-Back. Press Release. 2024.
9. Innovent Biologics. Mazdutide Shows Major Weight Loss in Adolescents with Obesity. Press Release. 2024.
10. Innovent Biologics. Mazdutide 9mg Achieves Up to 20.1% Weight Loss in GLORY-2 Study. Press Release. 2024.
11. Tan TM, Field BCT, McCullough KA, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy output and amelioration of hyperglycemia. Diabetes. 2013;62(4):1131-1138.
12. Salem V, Izzi-Engbeaya C, Coello C, et al. Glucagon increases energy output independently of brown adipose tissue start in humans. Diabetes Obes Metab. 2016;18(1):72-81.
13. Pocai A. Action and treatment possible of oxyntomodulin. Mol Metab. 2014;3(3):241-251.

---

9. RELATED PRODUCTS & INTERNAL LINKS

Complementary Weight Loss Peptides

• Semaglutide 5mg – Single GLP-1 agonist baseline
• Tirzepatide 5mg – Dual GIP/GLP-1 agonist competitor
• Retatrutide 5mg – Triple agonist next-generation
• Cagrilintide 5mg – Amylin agonist paired

Growth Hormone Peptides for Body Composition

• Tesamorelin 5mg – Visceral fat reduction
• Ipamorelin 5mg – Lean mass preservation
• Sermorelin 5mg – Natural GH rise
• CJC-1295 5mg – Long-acting GHRH
• GHRP-6 5mg – Potent GH secretagogue
• GHRP-2 5mg – Strong GH secretagogue
• Hexarelin 5mg – Most potent secretagogue

Recovery and Tissue Repair Peptides

• BPC-157 5mg – Gut health and tissue repair
• TB-500 5mg – Angiogenesis and healing

Essential Research Supplies

• Sterile Water 3mL – For peptide mixing
• Peptide Calculator – Free dosing calculator tool
• Shop All Peptides – Complete peptide catalog